2024-01-23 12:23:49 ET
More on Johnson & Johnson
- Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
- Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
- Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business
- Johnson & Johnson wins arbitration appeal against Genmab
- Johnson & Johnson posts Q4 beat as pharma and MedTech outperform
Read the full article on Seeking Alpha
For further details see:
Johnson & Johnson’s MedTech performance augurs well for industry: analysts